Study Finds H.I.V. Drugs Priced Out of Reach
New York Times, 28 January 2015 - A new study conducted by Harvard researchers and recently published in the New England Journal finds out that remedies to treat HIV/AIDS are priced out of reach for many patients who are enrolled in the America’s health insurance plans.
|
Despite warnings that such practices are illegal and discriminate people the analysis shows that a quarter of the plans are skirting these laws with drastic financial impact for patients: "A patient taking a common H.I.V. treatment, Atripla, would pay about $3,000 more a year in a restrictive plan compared with someone enrolled in a more generous plan, even after accounting for the fact that the more restrictive plans tended to charge lower monthly premiums". Source: Using Drugs to Discriminate — Adverse Selection in the Insurance Marketplace Jacobs et al. (2015). The New England Journal of Medicine |